Among patients with type 2 diabetes, no differences were found with biguanides vs DPP-4 inhibitors in major cardiac or cerebrovascular events, diabetic complications, or death. Biguanides vs ...

Dipeptidyl peptidase-4 (DPP-4), also known as the T-cell antigen CD26, is a multi-functional protein which, besides its catalytic activity, also functions as a binding protein and a ligand for a ...

DPP-4 inhibitors, also known as gliptins, are prescription drugs authorized for sale in Canada to treat type 2 diabetes in adults. Health Canada reviewed the increased potential risk of heart failure ...

Alogliptin (NESINA), a dipeptidyl peptidase IV (DPP-4) inhibitor, was approved by the FDA on January 25, 2013 to improve blood sugar control in adults with type 2 diabetes. This drug had been ...

DPP-4 exists as a membrane-bound form, widely expressed and enzymatically active on numerous cell types and different vascular beds... ...as well as a soluble form ...

Study results have validated that five routinely measured clinical values reliably identified patients with type 2 diabetes who had significantly different A1c responses to two important classes of ...

The results suggest that dipeptidyl peptidase-4 (DDP-4) inhibitors, which are widely prescribed in Germany, are not a cost-effective option despite lower drug pricing compared with empagliflozin.

5 Catholic Kwandong University College of Medicine Department of Medical Science, Gangneung-si, The Republic of Korea Background Dipeptidyl peptidase-4 inhibitors (DPP-4is) have been reported to ...